References
- Villegas VM, Hess DJ, Wildner A, Gold AS, Murray TG. Retinoblastoma. Curr Opin Ophthalmol. 2013;24:581–88. doi:10.1097/ICU.0000000000000002.
- Wong JR, Tucker MA, Kleinerman RA, Devesa SS. Retinoblastoma incidence patterns in the US Surveillance, Epidemiology, and End Results program. JAMA Ophthalmol. 2014;132(4):478–83. doi:10.1001/jamaophthalmol.2013.8001.
- Li SY, Chen SCC, Tsai CF, Sheu SM, Yeh JJ, Tsai CB. Incidence and survival of retinoblastoma in Taiwan: a nationwide population-based study 1998–2011. Br J Ophthalmol. 2016;100(6):839–42. doi:10.1136/bjophthalmol-2015-307211.
- Hernando E, Nahlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 2004;430:797–802. doi:10.1038/nature02820.
- Yang YQ, Li J, Yuan HF. Epidemiology and risk factors of retinoblastoma in Chongqing area. Int J Ophthalmol. 2016;9(7):984–88. doi:10.18240/ijo.2016.07.08.
- Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96(4):1297–325. doi:10.1152/physrev.00041.2015.
- Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74. doi:10.1038/nrg3074.
- Chen X, C C Y, Zhang X, You ZH. Long non-coding RNAs and complex diseases: from experimental results to computational models. Brief Bioinform. 2016;18:558–76.
- Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703–19. doi:10.4161/rna.20481.
- Bird L. lncRNA NKILA: a killer regulator. Nat Rev Immunol. 2018;18(11):666–67. doi:10.1038/s41577-018-0078-3.
- Hu C, Liu S, Han M, Wang Y, Xu C. Knockdown of lncRNA XIST inhibits retinoblastoma progression by modulating the miR-124/STAT3 axis. Biomed Pharmacother. 2018;107:547–54. doi:10.1016/j.biopha.2018.08.020.
- Yang G, Fu Y, Lu X, Wang M, Dong H, Li Q. LncRNA HOTAIR/miR-613/c-met axis modulated epithelial-mesenchymal transition of retinoblastoma cells. J Cell Mol Med. 2018;22(10):5083–96. doi:10.1111/jcmm.13796.
- L L B, Han F, Zhang XM, Li YY. LncRNA MT1JP acts as a tumor inhibitor via reciprocally regulating Wnt/β-Catenin pathway in retinoblastoma. Eur Rev Med Pharmacol Sci. 2018;22(13):4204–14. doi:10.26355/eurrev_201807_15414.
- Wei W, Liu Y, Lu Y, Yang B, Tang L. LncRNA XIST promotes pancreatic cancer proliferation through miR‐133a/EGFR. J Cell Biochem. 2017;118(10):3349–58. doi:10.1002/jcb.25988.
- Kong Q, Zhang S, Liang C, Zhang Y, Kong Q, Chen S, Qin J, Jin Y. LncRNA XIST functions as a molecular sponge of miR‐194‐5p to regulate MAPK1 expression in hepatocellular carcinoma cell. J Cell Biochem. 2018;119(6):4458–68. doi:10.1002/jcb.26540.
- Cheng Y, Chang Q, Zheng B, Xu J, Li H, Wang R. LncRNA XIST promotes the epithelial to mesenchymal transition of retinoblastoma via sponging miR-10. Eur J Pharmacol. 2018;22:210–16.
- Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–63. doi:10.1016/j.ccell.2016.03.010.
- Yang T, Li S, Liu J, Yin D, Yang X, Tang Q. lncRNA‐NKILA/NF‐κB feedback loop modulates laryngeal cancer cell proliferation, invasion, and radioresistance. Cancer Med. 2018;7(5):2048–63. doi:10.1002/cam4.1405.